Latest advances in novel cannabinoid CB 2 ligands for drug abuse and their therapeutic potential

Future Medicinal Chemistry

Volumn 4, Issue 2, 2012, Pages 187-204

  Yang, Peng ^a   Wang, Lirong ^a   Xie, Xiang Qun ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Endocannabinoids are found in the nervous and immune systems of animals and activate cannabinoid receptors. The endocannabinoid system represents a neuromodulator system consisting of endogenous ligands; enzymes and cannabinoid receptors (subtypes CB 1 and CB 2) that are involved in a variety of physiological processes including appetite; mood and memory; it mediates the psychoactive effects of cannabis; pain sensation

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; ALCOHOL; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; CAPSAICIN; COCAINE; DIAMORPHINE; DIAZEPAM; ENDOCANNABINOID; IMIDAZOLE DERIVATIVE; ISOTHIAZOLE DERIVATIVE; MESCALINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MORPHINE; MORPHOLINE DERIVATIVE; NICOTINE; NITROUS OXIDE; PHENCYCLIDINE; PSYCHOTROPIC AGENT; PYRAZOLE; PYRROLIDINE DERIVATIVE; RIMONABANT; SCAFFOLD PROTEIN; SULFONAMIDE; THIAZOLE DERIVATIVE; UNINDEXED DRUG;

ALLERGIC REACTION; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; DISORIENTATION; DROWSINESS; DRUG ABUSE; EUPHORIA; GASTROINTESTINAL DISEASE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; LIVER DISEASE; MICROGLIA; MULTIPLE SCLEROSIS; NONHUMAN; OBESITY; PAIN; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; TOBACCO; TRAUMATIC BRAIN INJURY; VENTRAL TEGMENTUM;

ANIMALS; HUMANS; LIGANDS; RECEPTOR, CANNABINOID, CB2; SUBSTANCE-RELATED DISORDERS;

EID: 84863016349     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.179     Document Type: Review

References (81)

1. 2 selective ligands. Curr. Med. Chem. 12(10), 1217-1237 (2005). (Pubitemid 40645483)
2. Nordstrom BR, Levin FR. Treatment of cannabis use disorders: a review of the literature. Am. J. Addict. 16(5), 331-342 (2007). (Pubitemid 47450754)
3. Tanda G, Goldberg SR. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms - a review of recent preclinical data. Psychopharmacology 169(2), 115-134 (2003). (Pubitemid 37129963)
4. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276(5321), 2048-2050 (1997). (Pubitemid 27443611)
5. Clapper JR, Mangieri RA, Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 56(Suppl. 1), 235-243 (2009).
6. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4(11), 873-884 (2003).
7. 1 receptor antagonism - or inverse agonism - as potential obesity treatment and other therapeutic use. J. Clin. Pharm. Ther. 32(3), 209-231 (2007). (Pubitemid 46699514)
8. Justinova Z, Panlilio LV, Goldberg SR. Drug addiction. Curr. Top. Behav. Neurosci. 1, 309-346 (2009).
9. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284), 561-564 (1990).
10. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441), 61-65 (1993). (Pubitemid 23305569)
11. 1 receptor: determination of helix ends and helix orientation. Life Sci. 56(23-24), 1971-1982 (1995).
12. Onaivi ES, Chakrabarti A, Chaudhuri G. Cannabinoid receptor genes. Prog. Neurobiol. 48(4-5), 275-305 (1996). (Pubitemid 26191216)
13. 2 receptor. Protein 53(2), 307-319 (2003). (Pubitemid 37193825)
14. Howlett AC, Barth F, Bonner TI et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54(2), 161-202 (2002). (Pubitemid 34575709)
15. 1 receptors in human ileum. Br. J. Pharmacol. 125(7), 1393-1395 (1998). (Pubitemid 28548549)
16. Pertwee RG. Cannabinoid receptors and pain. Prog. Neurobiol. 63(5), 569-611 (2001). (Pubitemid 32115433)
17. Szabo B, Nordheim U, Niederhoffer N. Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J. Pharmacol. Exp. Ther. 297(2), 819-826 (2001). (Pubitemid 32378017)
18. 2 cannabinoid receptor. Cancer Res. 61(15), 5784-5789 (2001). (Pubitemid 32769095)
19. 2 receptor: a new target for controlling neural cell survival? Trends Pharmacol. Sci. 28(1), 39-45 (2007). (Pubitemid 46038536)
20. 2), their distribution, ligands and functional involvement in nervous system structures: a short review. Pharmacol. Biochem. Behav. 90(4), 501-511 (2008).
21. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 296(5568), 678-682 (2002).
22. 2 receptor. Curr. Top. Med. Chem. 8(3), 187-204 (2008). (Pubitemid 351795769)
23. 1 receptor antagonists as potential pharmacotherapies for drug abuse disorders. Int. Rev. Psychiatry 21(2), 134-142 (2009).
24. 1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behav. Pharmacol. 16(5-6), 275-296 (2005). (Pubitemid 41404802)
25. Rinaldi-Carmona M, Barth F, Heaulme M et al. SR141716A: a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350(2-3), 240-244 (1994). (Pubitemid 24268029)
26. Valenzano KJ, Tafesse L, Lee G et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48(5), 658-672 (2005). (Pubitemid 40462406)
27. Berdyshev EV. Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids 108(1-2), 169-190 (2000).
28. 2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 275(1), 605-612 (2000). (Pubitemid 30039024)
29. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410(6828), 588-592 (2001). (Pubitemid 32267203)
30. 2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur. J. Neurosci. 23(6), 1530-1538 (2006).
31. 2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One 3(2), e1640 (2008).
32. 2 receptors in human brain inflammation. Br. J. Pharmacol. 153(2), 277-285 (2008).
33. 2 receptors in the brain. Neuropsychobiology 54(4), 231-246 (2006).
34. 2 receptor in alcohol preference in mice and alcoholism in humans. Pharmacogenomics J. 7(6), 380-385 (2007). (Pubitemid 350187449)
35. 2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann. NY Acad. Sci. 1139, 434-449 (2008).
36. Uhl GR, Ishiguro H, Onaivi ES et al. Molecular neurobiological methods in marijuana-cannabinoid research. Methods Mol. Med. 123, 1-17 (2006).
37. 2 receptors modulate cocaine's actions in mice. Nat. Neurosci. 14, 1160-1166 (2011).
38. 2 receptors in health and disease. Curr. Med. Chem. 17(14), 1393-1410 (2010).
39. 2 cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J. Biol. Chem. 283(19), 13320-13329 (2008).
40. Dvorak M, Watkinson A, Mcglone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm. Res. 52(6), 238-245 (2003). (Pubitemid 36791930)
41. Karsak M, Gaffal E, Date R et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316(5830), 1494-1497 (2007). (Pubitemid 46906619)
42. 2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol. 5(2), 73-80 (2007). (Pubitemid 47019422)
43. 2 receptor activation decreases cerebral infarction in a mouse focal ischemia/ reperfusion model. J. Cereb. Blood Flow Metab. 27(7), 1387-1396 (2007). (Pubitemid 46985356)
44. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem. Phys. Lipids 121(1-2), 173-190 (2002). (Pubitemid 36050105)
45. Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. Handb. Exp. Pharmacol. (168), 509-554 (2005).
46. 2 receptor agonists. Curr. Med. Chem. 14(8), 917-936 (2007). (Pubitemid 46863619)
47. 2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br. J. Pharmacol. 153(2), 319-334 (2008).
48. 2- selective agonist GW405833. Pain 143(3), 206-212 (2009).
49. 2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology 60(2-3), 244-251 (2011).
50. Guindon J, Hohmann AG. The endocannabinoid system and cancer: therapeutic implication. Br. J. Pharmacol. 163(7), 1447-1463 (2011).
51. Qamri Z, Preet A, Nasser MW et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol. Cancer Ther. 8(11), 3117-3129 (2009).
52. Caffarel MM, Andradas C, Mira E et al. CBs reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol. Cancer 9, 196 (2010).
53. Idris AI, Ralston SH. CBs and bone: friend or foe? Calcif. Tissue Int. 87(4), 285-297 (2010).
54. 2, regulates bone mass. Proc. Natl Acad. Sci. USA 103(3), 696-701 (2006). (Pubitemid 43153088)
55. Idris AI, Van 'T Hof RJ, Greig IR et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med. 11(7), 774-779 (2005). (Pubitemid 41021210)
56. Rossi F, Siniscalco D, Luongo L et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone 44(3), 476-484 (2009).
57. Izzo AA, Camilleri M. Emerging role of CBs in gastrointestinal and liver diseases: basic and clinical aspects. Gut 57(8), 1140-1155 (2008).
58. 2 receptor in cirrhotic rats. J. Pharmacol. Exp. Ther. 324(2), 475-483 (2008). (Pubitemid 351185849)
59. Wei Y, Wang X, Wang L. Presence and regulation of cannabinoid receptors in human retinal pigment epithelial cells. Mol. Vis. 15, 1243-1251 (2009).
60. 2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. Mol. Cell Neurosci. 38(4), 526-536 (2008).
61. 2 receptor. Curr. Top. Med. Chem. 8(3), 187-204 (2008). (Pubitemid 351795769)
62. Reggio PH. Cannabinoid receptors and their ligands: ligand-ligand and ligand-receptor modeling approaches. Handb. Exp. Pharmacol. 168(CBs), 247-281 (2005).
63. Padgett LW. Recent developments in cannabinoid ligands. Life Sci. 77(14), 1767-1798 (2005). (Pubitemid 41078745)
64. 2 receptor antagonists with high binding efficiencies. Bioorg. Med. Chem. Lett. 20, 1084-1089 (2010).
65. 2 cannabinoid receptor agonists. Bioorg. Med. Chem. Lett. 19, 5931-5935 (2009).
66. 2 selective agonists. Bioorg. Med. Chem. Lett. 19, 1604-1609 (2009).
67. 2 agonists: optimization of drug-like properties and target independent parameters. Bioorg Med Chem. Lett 21, 4276-4280 (2011).
68. 1 selectivity and implications for in vivo analgesic efficacy. Bioorg. Med. Chem. Lett. 21, 2354-2358 (2011).
69. 2 agonist for the treatment of chronic pain. J. Med. Chem. 52, 5785-5788 (2009).
70. Pasquini S, Ligresti A, Mugnaini C et al. Investigations on the 4-quinolone-3- carboxylic acid motif. 3. Synthesis, structure- affinity relationships and pharmacological characterization of 6-substituted 4-quinolone- 3-carboxamides as highly selective CB-2 receptor ligands. J. Med. Chem. 53, 5915-5928 (2010).
71. Pasquini S, De RM, Pedani V et al. Investigations on the 4-quinolone-3- carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice. J. Med. Chem. 54, 5444-5453 (2011).
72. 2 receptor. Bioorg. Med. Chem. 18, 7809-7815 (2010).
73. Burdick D, De OR, Guzzo P et al. Synthesis and structure-activity relationship of substitutions at the C-1 position of D9- tetrahydrocannabinol. Bioorg. Med. Chem. Lett. 20, 1424-1426 (2010).
74. 2 receptor inhibitors. Bioorg. Med. Chem. Lett. 20, 608-611 (2010).
75. 2 receptor ligands. Bioorg. Med. Chem. Lett. 20, 6785-6789 (2010).
76. 2 selective sulfamoyl benzamides: optimization of the amide functionality. Bioorg. Med. Chem. Lett. 19, 309-313 (2009).
77. 2 agonists with improved in vitro metabolic stability. Bioorg. Med. Chem. Lett. 20, 387-391 (2010).
78. 2. A combined NMR and CoMFA approach. J. Med. Chem. 49(2), 625-636 (2006). (Pubitemid 43158442)
79. 2 antagonist search. J. Comput. Info. Modeling 47, 1626-1637 (2007 ).
80. 2 agonists. Bioorg. Med. Chem. Lett. 19, 5004-5008 (2009).
81. Gertsch J, Leonti M, Raduner S et al. β-caryophyllene is a dietary CB. Proc. Natl Acad. Sci. USA 105(26), 9099-9104 (2008).